← Back to Clinical Trials
Recruiting NCT06745947

NCT06745947 Behavioral Economic Intervention to Improve HIV Behaviors in Sexual Minority Individuals

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06745947
Status Recruiting
Phase
Sponsor The University of Texas Health Science Center at San Antonio
Condition HIV Prevention
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2025-03-03
Primary Completion 2027-01-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 34 Years
Study Type INTERVENTIONAL
Interventions
EFT

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2025-03-03 with a primary completion date of 2027-01-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This research study is testing a new behavioral therapy called Episodic Future Thinking or EFT can help people reduce drug use and risky sexual behaviors while helping them adhere to their HIV prevention medication (PrEP). Participants will be randomly assigned to one of two groups. One group will receive standard care, which includes counseling on HIV prevention, drug use reduction, and sexual health. The other group will receive standard care plus a new program called Episodic Future Thinking (EFT), where participants will think about and plan for their future goals using a mobile app and counseling sessions. Study procedures that are not part of regular care include filling out surveys, providing blood, urine, and swab samples for testing, and using the EFT app.

Eligibility Criteria

Inclusion Criteria: * Adults 18 - 34 years of age * HIV negative (assessed via Rapid HIV Antibody Test) * Identify as gay, or bisexual * Recent (past 3 months) methamphetamine use * Currently prescribed and taking HIV PrEP medication * Self-reported HIV PrEP nonadherence in the past three months * Urine screen test for PrEP nonadherence * Self-reported condomless anal sex or a STI in the past three months * Able to attend all study visits * Fluent in English Exclusion Criteria: * Currently receiving treatment for any substance use disorder, * HIV positive * Having a medical or psychiatric illness that in the opinion of the PI would interfere with study participation * Unable to provide informed consent * Unable to attend protocol directed study visits * Any plans that would preclude study completion (e.g. surgery, major medical treatments such as chemotherapy, incarceration, travel/moving out of San Antonio, Texas)

Contact & Investigator

Central Contact

Emeka Okafor, PhD, MPH

✉ okaforcn@uthscsa.edu

📞 210-450-7377

Principal Investigator

Emeka Okafor, PhD, MPH

PRINCIPAL INVESTIGATOR

The University of Texas Health Science Center at San Antonio

Frequently Asked Questions

Who can join the NCT06745947 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 34 Years, studying HIV Prevention. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06745947 currently recruiting?

Yes, NCT06745947 is actively recruiting participants. Contact the research team at okaforcn@uthscsa.edu for enrollment information.

Where is the NCT06745947 trial being conducted?

This trial is being conducted at San Antonio, United States.

Who is sponsoring the NCT06745947 clinical trial?

NCT06745947 is sponsored by The University of Texas Health Science Center at San Antonio. The principal investigator is Emeka Okafor, PhD, MPH at The University of Texas Health Science Center at San Antonio. The trial plans to enroll 60 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology